Bristol-Myers Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate-214 study in Patients with Advanced or Metastatic RCC

 Bristol-Myers Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate-214 study in Patients with Advanced or Metastatic RCC

Bristol-Myers Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-III CheckMate-214 study in Patients with Advanced or Metastatic RCC

Shots:

  • The P-III CheckMate-214 study involves assessing of Opdivo (nivolumab, 3mg/kg) + Yervoy (ipilimumab,1mg/kg) vs sunitinib (50mg qd @4wks.) in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC)
  • P-III Checkmate study results @30 months: OS (60% vs 47%); ORR (42% vs 29%); CR (11% vs 1%), @ intention-to-treat (ITT): OS (64% vs 56%); ORR (41% vs 34%); CR (11% vs 2%)
  • Opdivo (nivolumab) is a PD-1 immune checkpoint inhibitor targeted for cancer cells and is approved in 65 countries including the US, EU, Japan & China

Click here to read full press release/ article | Ref: BUSINESS WIRE | Image: Glassdoor

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post